OBJECTIVES: To compare the distribution of tenofovir in sheep vaginal lumen, tissue, and plasma following topical delivery of the antiretroviral drug from intravaginal rings, either as tenofovir or the disoproxil fumarate prodrug. DESIGN: Comparative pharmacokinetic study in sheep. METHOD: Intravaginal rings formulated to achieve equivalent release rates of tenofovir and its disoproxil fumarate prodrug were evaluated for 28 days in sheep, with four animals in each group. Drug concentrations were measured by high-performance liquid chromatography-mass spectrometry. RESULTS: Tenofovir levels in cervicovaginal lavage were indistinguishable (P > 0.30) in both groups, but tissue levels in animals receiving the prodrug were 86-fold higher than those receiving tenofovir, and approximately 50 times higher than the level shown to be protective of HIV infection in the CAPRISA 004 trial. CONCLUSION: This is the first study to compare the pharmacokinetics of tenofovir and its disoproxil fumarate prodrug administered topically to the vaginal tract. These in-vivo data show that the prodrug leads to significantly higher drug tissue levels than tenofovir, a finding that may have important implications for the development of preexposure prophylaxis strategies based on topical delivery of antivirals to the female genital tract.
OBJECTIVES: To compare the distribution of tenofovir in sheep vaginal lumen, tissue, and plasma following topical delivery of the antiretroviral drug from intravaginal rings, either as tenofovir or the disoproxil fumarate prodrug. DESIGN: Comparative pharmacokinetic study in sheep. METHOD: Intravaginal rings formulated to achieve equivalent release rates of tenofovir and its disoproxil fumarate prodrug were evaluated for 28 days in sheep, with four animals in each group. Drug concentrations were measured by high-performance liquid chromatography-mass spectrometry. RESULTS:Tenofovir levels in cervicovaginal lavage were indistinguishable (P > 0.30) in both groups, but tissue levels in animals receiving the prodrug were 86-fold higher than those receiving tenofovir, and approximately 50 times higher than the level shown to be protective of HIV infection in the CAPRISA 004 trial. CONCLUSION: This is the first study to compare the pharmacokinetics of tenofovir and its disoproxil fumarate prodrug administered topically to the vaginal tract. These in-vivo data show that the prodrug leads to significantly higher drug tissue levels than tenofovir, a finding that may have important implications for the development of preexposure prophylaxis strategies based on topical delivery of antivirals to the female genital tract.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: John A Moss; Amanda M Malone; Thomas J Smith; Sean Kennedy; Etana Kopin; Cali Nguyen; Josh Gilman; Irina Butkyavichene; Kathleen L Vincent; Massoud Motamedi; David R Friend; Meredith R Clark; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2011-11-28 Impact factor: 5.191
Authors: Peter L Anderson; Jennifer J Kiser; Edward M Gardner; Joseph E Rower; Amie Meditz; Robert M Grant Journal: J Antimicrob Chemother Date: 2010-11-30 Impact factor: 5.790
Authors: J van Gelder; S Deferme; L Naesens; E De Clercq; G van den Mooter; R Kinget; P Augustijns Journal: Drug Metab Dispos Date: 2002-08 Impact factor: 3.922
Authors: Kathleen L Vincent; Nigel Bourne; Brent A Bell; Gracie Vargas; Alai Tan; Daniel Cowan; Lawrence R Stanberry; Susan L Rosenthal; Massoud Motamedi Journal: Sex Transm Dis Date: 2009-05 Impact factor: 2.830
Authors: John A Moss; Amanda M Malone; Thomas J Smith; Sean Kennedy; Cali Nguyen; Kathleen L Vincent; Massoud Motamedi; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2013-06-10 Impact factor: 5.191
Authors: Christopher McConville; James M Smith; Clare F McCoy; Priya Srinivasan; James Mitchell; Angela Holder; Ron A Otten; Salvatore Butera; Gustavo F Doncel; David R Friend; R Karl Malcolm Journal: Drug Deliv Transl Res Date: 2015-02 Impact factor: 4.617
Authors: Manjula Gunawardana; Madeline Mullen; Jennifer Yoo; Paul Webster; John A Moss; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2014-02-03 Impact factor: 5.191
Authors: Marc M Baum; Irina Butkyavichene; Scott A Churchman; Gilbert Lopez; Christine S Miller; Thomas J Smith; John A Moss Journal: Int J Pharm Date: 2015-09-16 Impact factor: 5.875
Authors: James M Smith; Rachna Rastogi; Ryan S Teller; Priya Srinivasan; Pedro M M Mesquita; Umadevi Nagaraja; Janet M McNicholl; R Michael Hendry; Chuong T Dinh; Amy Martin; Betsy C Herold; Patrick F Kiser Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205
Authors: John A Moss; Priya Srinivasan; Thomas J Smith; Irina Butkyavichene; Gilbert Lopez; Amanda A Brooks; Amy Martin; Chuong T Dinh; James M Smith; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2014-06-16 Impact factor: 5.191
Authors: John A Moss; Amanda M Malone; Thomas J Smith; Irina Butkyavichene; Cassandra Cortez; Joshua Gilman; Sean Kennedy; Etana Kopin; Cali Nguyen; Preetha Sinha; R Michael Hendry; Patricia Guenthner; Angela Holder; Amy Martin; Janet McNicholl; James Mitchell; Chou-Pong Pau; Priya Srinivasan; James M Smith; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2012-09-10 Impact factor: 5.191
Authors: John A Moss; Irina Butkyavichene; Scott A Churchman; Manjula Gunawardana; Rob Fanter; Christine S Miller; Flora Yang; Jeremiah T Easley; Mark A Marzinke; Craig W Hendrix; Thomas J Smith; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2016-05-23 Impact factor: 5.191
Authors: Todd J Johnson; Meredith R Clark; Theodore H Albright; Joel S Nebeker; Anthony L Tuitupou; Justin T Clark; Judit Fabian; R Tyler McCabe; Neelima Chandra; Gustavo F Doncel; David R Friend; Patrick F Kiser Journal: Antimicrob Agents Chemother Date: 2012-09-24 Impact factor: 5.191